Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein expressed primarily in astrocytes, serving as a specific marker of astrocytic activation and gliosis. In Alzheimer's disease, GFAP levels in blood and cerebrospinal fluid (CSF) have emerged as a promising biomarker reflecting neuroinflammation and astrocytic responses to amyloid and tau pathology.
- Astrocyte activation and reactive gliosis
- Neuroinflammatory burden in AD
- Blood-brain barrier dysfunction
GFAP is released by activated astrocytes in response to:
| Study Cohort |
Sensitivity |
Specificity |
AUC |
Notes |
| Preclinical AD |
75-82% |
78-85% |
0.82 |
Elevated before symptoms |
| MCI due to AD |
80-88% |
82-88% |
0.88 |
Higher than MCI-stable |
| Clinical AD |
85-92% |
85-90% |
0.91 |
Strongest signal |
- GFAP elevated 5-10 years before clinical symptoms
- Correlates with amyloid positivity in preclinical stages
- May identify patients at highest risk for progression
- Higher GFAP levels associate with faster cognitive decline
- Correlates with hippocampal atrophy rate
- Predicts conversion from MCI to AD
- AD vs. FTD: GFAP higher in AD
- AD vs. PD: GFAP significantly elevated in AD
- AD vs. Lewy body dementia: Mixed results, overlapping values
- GFAP: Astrocyte-specific, rises early
- NfL: Neuronal injury, rises later in disease
- Combined: Improved diagnostic accuracy, progression prediction
- p-Tau: Reflects tau pathology directly
- GFAP: Reflects inflammatory response
- Complementary: Different biological pathways
- GFAP + p-Tau combination shows best performance for early detection
- GFAP rises earliest; p-tau reflects actual pathology
- Combined panel AUC reaches 0.95
| Panel |
AUC |
Clinical Utility |
| GFAP + p-Tau181 |
0.92 |
Best for early detection |
| GFAP + NfL |
0.89 |
Good for progression |
| GFAP + Aβ42/40 |
0.88 |
Amyloid confirmation |
| GFAP + p-Tau + NfL |
0.95 |
Comprehensive |
- Advantages: Minimal invasiveness, easily repeatable
- Challenge: Lower concentration, requires ultrasensitive assays
- Platforms: Simoa, Ella, Lumipulse
- Correlation with CSF: r = 0.70-0.80
- Reference range: ~100-200 pg/mL in healthy controls
- Advantages: Higher concentrations, more established
- Disadvantage: Lumbar puncture required
- Standardization: More mature assay development
- Reference ranges: Well-established
- CSF reference range: ~15-35 ng/mL
GFAP serves as an astrogliosis marker within the AT(N) biomarker classification system:
| AT(N) Component |
Biomarker |
What It Measures |
| A (Amyloid) |
Aβ42/40, PET |
Amyloid pathology |
| T (Tau) |
p-Tau181/217/231, Tau PET |
Tau pathology |
| (N) (Neurodegeneration) |
NfL, atrophy |
Neuronal injury |
| Astrocyte |
GFAP |
Astrocytic activation |
- A+GFAP+: Amyloid with astrocyte activation
- A+GFAP+NfL+: Full AD signature
- GFAP elevated, A-T-: Non-AD astrocytosis
¶ Regulatory and Commercial Status
- FDA: No FDA-cleared GFAP test for AD yet
- Research Use Only: Available on multiple platforms
- Companion diagnostic: Potential for anti-amyloid therapy selection
- LDT development: Several labs developing GFAP LDTs
| Platform |
Sample Type |
Availability |
Approximate Cost |
| Lumipulse G |
CSF |
Clinical labs |
$150-250 |
| Simoa |
Plasma/Serum |
Research |
$80-150 |
| Ella |
Plasma/Serum |
Research/Clinical |
$100-200 |
| MSD |
Plasma/Serum |
Research |
$120-180 |
| ALZpath |
Plasma |
Clinical |
$100-150 |
| Method |
Cost per Test |
Annual Monitoring |
| Blood GFAP |
$50-150 |
$200-600 |
| CSF Biomarker Panel |
$300-500 |
$1,200-2,000 |
| Amyloid PET |
$3,000-5,000 |
$6,000-10,000 |
| MRI |
$1,000-2,000 |
$4,000-8,000 |
- GFAP elevation validated in AD vs. controls
- J-ADNI cohort data available
- Population-specific cutoffs: 127 pg/mL (vs. 100 pg/mL Western)
- Good correlation with Japanese cognitive tests
- Strong diagnostic performance (AUC 0.85-0.90)
- CANDI study data
- Population-specific considerations for BMI adjustment
- Reference range: 95-180 pg/mL
- Strong correlation with amyloid PET
- GFAP + p-Tau217 combination validated
- KBASE cohort data
- Population-specific cutoffs being developed
| Population |
GFAP Cutoff (pg/mL) |
Notes |
| Western |
100-110 |
Standard reference |
| Japanese |
127 |
Higher baseline |
| Chinese |
95-130 |
Variable by assay |
| Korean |
115 |
Similar to Western |
- Early detection: Higher impact in populations with limited MRI/PET access
- Cost-effectiveness: Blood GFAP ~$50-100 vs. PET ~$3000+
- Home collection potential: Dried blood spot compatible
- Sample handling: Centrifuge within 2 hours of collection
- Storage: -80°C preferred, -20°C acceptable short-term
- Freeze-thaw: Limit to 3 cycles maximum
- Hemolysis: Moderate hemolysis can increase GFAP 10-15%
- Age: GFAP increases ~1-2% per year after age 60
- Sex: Slightly higher in males
- BMI: Inverse correlation - lower in obesity
- Kidney function: Reduced clearance in renal impairment
- GFAP levels show dynamic changes with anti-amyloid treatment
- Lecanemab: GFAP reduction associated with amyloid removal
- Donanemab: GFAP changes predict clinical response
- Aduhelm: GFAP used for patient selection
- Early GFAP reduction may predict clinical benefit
- GFAP monitoring helps identify ARIA risk
- Combination with NfL for comprehensive response assessment
- Enrollment biomarker: Enrich trials with GFAP-positive subjects
- Outcome measure: Treatment response reflected in GFAP changes
- Mechanistic marker: Astrocyte-targeting therapy efficacy
- Biomarker trajectories: GFAP rises earliest among blood biomarkers
- Predictive modeling: GFAP improves risk prediction algorithms
- Multi-modal integration: Combined with MRI, PET, cognitive tests
- Overlap: Elevated in other neurological conditions (stroke, trauma, MS, PSP, CBD)
- Age effects: Baseline GFAP increases with age (~1-2%/year after 60)
- Assay variability: Different platforms have different cutoffs
- Specificity: Not AD-specific, reflects general neuroinflammation
- Timing: Changes are subtle in earliest preclinical stages
- Stroke and acute brain injury
- Multiple sclerosis
- Progressive supranuclear palsy
- Corticobasal degeneration
- Traumatic brain injury
- Brain tumors
- Point-of-care testing: Rapid blood GFAP for screening
- Home monitoring: Capillary blood collection
- Multimodal algorithms: GFAP + p-Tau + NfL panels
- Digital integration: EHR integration for screening programs
- Standardized reference materials
- Clinical validation studies
- Regulatory approval pathways
- Population-specific cutoffs
- Standardization across platforms